Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387206505> ?p ?o ?g. }
Showing items 1 to 68 of
68
with 100 items per page.
- W4387206505 endingPage "e226" @default.
- W4387206505 startingPage "e226" @default.
- W4387206505 abstract "Treating Glioblastoma remains a major challenge. Radiotherapy has a long-standing role in extending survival, but almost all tumors are expected to recur and be fatal. Historic dose-escalation studies do not yield additional benefit beyond the current 60 Gy dose. Further therapeutic improvement can be gained with radiosensitizers. An undiscovered potential radiosensitization approach may exist in inhibiting the N-myristoylation pathways upregulated in malignant cells. Inhibiting this pathway has been shown to have pleotropic effects including decreasing PARP-1 activity and other cancer-driving pathways that may synergize with radiotherapy. This is a first report in using a targeted N-myristoyltransferase (NMT) inhibitor as a radiosensitizer in glioblastoma.Immortalized glioma cell lines (U87 and U251) and patient-derived de novo (ED501) and post-chemoradiation recurrent (ED512) cell lines were used to a NMT1/2 inhibitor with radiotherapy. Cell surface expression levels for NMT1 and NMT2 were established using immunofluorescence microscopy. In vitro cell viability studies via mitochondrial reduction of resazurin dye and clonogenic assays were done with single fraction 2 & 4 Gy irradiation with 5 days of drug exposure (5-150 nM 3 days prior to irradiation and 2 days post) to account for drug pharmacodynamics. PARP-1 expression by western blot was tested with exposure to drug and/or radiation. Whole exome sequencing and methylation profiling were done to find predictive markers of radiosensitization.Preliminary results show significant radiosensitization effect with a dose enhancement factor ranging from 1.33 to 2.71x higher than radiation alone. The amount of radiosensitization varied per cell line, with U251 and ED512 being more sensitive. The cell line sensitivity was not reliably predicted by the NMT cell surface receptor expression. PARP-1 activity increased with radiotherapy but was inhibited with drug exposure. Exome sequencing showed the radiosensitizing effect correlated with mutations in DNA damage repair and myristoylation pathways.N-myristoylation inhibition appears to be a novel method of radiosensitization for glioblastoma. N-myristoylation affects multiple oncogenic pathways including PARP-1 downregulation, which impedes DNA damage repair and may be what leads to radiosensitization. Future studies are aimed at further predictive markers and in vivo efficacy." @default.
- W4387206505 created "2023-09-30" @default.
- W4387206505 creator A5010691206 @default.
- W4387206505 creator A5010691664 @default.
- W4387206505 creator A5036663495 @default.
- W4387206505 creator A5073726500 @default.
- W4387206505 date "2023-10-01" @default.
- W4387206505 modified "2023-10-17" @default.
- W4387206505 title "Radiosensitization of Glioblastoma Using Targeted Inhibition of N-Myristoylation" @default.
- W4387206505 doi "https://doi.org/10.1016/j.ijrobp.2023.06.1135" @default.
- W4387206505 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37784916" @default.
- W4387206505 hasPublicationYear "2023" @default.
- W4387206505 type Work @default.
- W4387206505 citedByCount "0" @default.
- W4387206505 crossrefType "journal-article" @default.
- W4387206505 hasAuthorship W4387206505A5010691206 @default.
- W4387206505 hasAuthorship W4387206505A5010691664 @default.
- W4387206505 hasAuthorship W4387206505A5036663495 @default.
- W4387206505 hasAuthorship W4387206505A5073726500 @default.
- W4387206505 hasConcept C117262875 @default.
- W4387206505 hasConcept C126322002 @default.
- W4387206505 hasConcept C128473837 @default.
- W4387206505 hasConcept C2776428644 @default.
- W4387206505 hasConcept C2777389519 @default.
- W4387206505 hasConcept C2778227246 @default.
- W4387206505 hasConcept C502942594 @default.
- W4387206505 hasConcept C509974204 @default.
- W4387206505 hasConcept C53227056 @default.
- W4387206505 hasConcept C54355233 @default.
- W4387206505 hasConcept C71924100 @default.
- W4387206505 hasConcept C81885089 @default.
- W4387206505 hasConcept C86803240 @default.
- W4387206505 hasConcept C98274493 @default.
- W4387206505 hasConceptScore W4387206505C117262875 @default.
- W4387206505 hasConceptScore W4387206505C126322002 @default.
- W4387206505 hasConceptScore W4387206505C128473837 @default.
- W4387206505 hasConceptScore W4387206505C2776428644 @default.
- W4387206505 hasConceptScore W4387206505C2777389519 @default.
- W4387206505 hasConceptScore W4387206505C2778227246 @default.
- W4387206505 hasConceptScore W4387206505C502942594 @default.
- W4387206505 hasConceptScore W4387206505C509974204 @default.
- W4387206505 hasConceptScore W4387206505C53227056 @default.
- W4387206505 hasConceptScore W4387206505C54355233 @default.
- W4387206505 hasConceptScore W4387206505C71924100 @default.
- W4387206505 hasConceptScore W4387206505C81885089 @default.
- W4387206505 hasConceptScore W4387206505C86803240 @default.
- W4387206505 hasConceptScore W4387206505C98274493 @default.
- W4387206505 hasIssue "2" @default.
- W4387206505 hasLocation W43872065051 @default.
- W4387206505 hasLocation W43872065052 @default.
- W4387206505 hasOpenAccess W4387206505 @default.
- W4387206505 hasPrimaryLocation W43872065051 @default.
- W4387206505 hasRelatedWork W1969094967 @default.
- W4387206505 hasRelatedWork W2040830156 @default.
- W4387206505 hasRelatedWork W2344922343 @default.
- W4387206505 hasRelatedWork W2560629363 @default.
- W4387206505 hasRelatedWork W2705316978 @default.
- W4387206505 hasRelatedWork W2745825872 @default.
- W4387206505 hasRelatedWork W3005634848 @default.
- W4387206505 hasRelatedWork W3013154413 @default.
- W4387206505 hasRelatedWork W4220865729 @default.
- W4387206505 hasRelatedWork W4311687976 @default.
- W4387206505 hasVolume "117" @default.
- W4387206505 isParatext "false" @default.
- W4387206505 isRetracted "false" @default.
- W4387206505 workType "article" @default.